Ads
related to: antiparkinson agents- Get Involved Today
Join our mission to end Parkinson's
You can make a difference
- Parkinson's Research News
The latest developments in research
Our research progress to date
- Get Involved Today
theoxfordcenter.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Pages in category "Antiparkinsonian agents" The following 52 pages are in this category, out of 52 total. This list may not reflect recent changes. A. Amantadine;
Currently, no proven neuroprotective agents or treatments are available for PD. While still theoretical, neuroprotective therapy is based on the idea that certain neurons that produce dopamine and are susceptible to premature degeneration and cell death can be protected by the introduction of neuroprotective pharmaceuticals .
Tolcapone is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa or levodopa/benserazide medications. Levodopa is a prodrug for dopamine, which reduces Parkinson symptoms; carbidopa and benserazide are aromatic L-amino acid decarboxylase (AADC) inhibitors.
Peripherally selective DDCIs incapable of crossing the protective blood–brain barrier (BBB) are used in augmentation of L-DOPA (levodopa) in the treatment of Parkinson's disease (PD) to block the conversion of L-DOPA into dopamine outside the brain, for the purpose of reducing adverse side effects. [3]
ATC code N04 Anti-parkinson drugs is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
Dihydroergocryptine (DHEC), sold under the brand names Almirid and Cripar among others, is a dopamine agonist of the ergoline group that is used as an antiparkinson agent in the treatment of Parkinson's disease. [1] It is taken by mouth. [citation needed]
Safinamide is the first antiparkinson medication to be approved for ten years. [25] Safinamide was approved by US FDA in March 2017 for people with Parkinsons taking levodopa/carbidopa during "off" episodes. [26] [27]
Budipine (brand name Parkinsan) is an antiparkinson agent marketed for the treatment of Parkinson's disease. [2] [3] [4]While its exact mechanism of action is not well characterized, [2] it is believed to be an NMDA receptor antagonist, [5] [6] but also promoting the synthesis of dopamine.
Ads
related to: antiparkinson agentstheoxfordcenter.com has been visited by 10K+ users in the past month